Julien P N Papillon, Christopher M Adams, Qi-Ying Hu, Changgang Lou, Alok K Singh, Chun Zhang, Jose Carvalho, Srinivan Rajan, Adam Amaral, Michael E Beil, Fumin Fu, Eric Gangl, Chii-Whei Hu, Arco Y Jeng, Daniel LaSala, Guiqing Liang, Michael Logman, Wieslawa M Maniara, Dean F Rigel, Sherri A Smith, Gary M Ksander
CYP11B2, the aldosterone synthase, and CYP11B1, the cortisol synthase, are two highly homologous enzymes implicated in a range of cardiovascular and metabolic diseases. We have previously reported the discovery of LCI699, a dual CYP11B2 and CYP11B1 inhibitor that has provided clinical validation for the lowering of plasma aldosterone as a viable approach to modulate blood pressure in humans, as well normalization of urinary cortisol in Cushing's disease patients. We now report novel series of aldosterone synthase inhibitors with single-digit nanomolar cellular potency and excellent physicochemical properties...
June 11, 2015: Journal of Medicinal Chemistry